Thromboprophylaxis in primary brain cancer
Bleeding, Thrombosis and Vascular Biology · Published 2026-04-16 · DOI 10.4081/btvb.2026.455
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.4081/btvb.2026.455
Abstract
Venous thromboembolism represents a major source of morbidity and mortality in patients with cancer. Patients with intracranial malignancies, notably high-grade glioma, experience a particularly elevated thrombotic risk. At the same time, these patients are uniquely vulnerable to intracranial hemorrhage, which may occur spontaneously during the disease course even without exposure to anticoagulant therapy. This competing risk profile presents a substantial clinical challenge, as measures designed to avert life-threatening thromboembolic incidents may concurrently elevate the risk of catastrophic intracranial hemorrhage. Consequently, the role of thromboprophylaxis in patients with intracranial tumors remains uncertain. In this review, we critically assess the available evidence on thromboprophylaxis in this population, addressing its risks and potential benefits across diverse clinical settings.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- In this issue · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Development of a shared decision-making tool for gene therapy in hemophilia A in Italy · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Hormones, cancer, and thrombosis: sex-specific mechanisms at the interface of hemostasis and vascular biology · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Platelet-derived thromboxane A2 induces cyclooxygenase-2 and epithelial-mesenchymal transition marker genes in U-87MG human glioblastoma cells · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- To P or not to P. That is the wrong question. · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practice · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors · Bleeding, Thrombosis and Vascular Biology · 2025 · Same journal
- Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next? · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal
- Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy · Bleeding, Thrombosis and Vascular Biology · 2026 · Same journal